Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TristelTSNLF 95 3-Year EBITDA Growth Rate is 17.90% as of Dec. 2025, which is 1% above its 10-year median of 17.80. GuruFocus rates TSNLF with a GF Score™ of 95/100 and a GF Value™ of $6.18 (Fairly Valued). The stock has 1 warning sign investors should review. Among 691 Medical Devices & Instruments companies, Tristel ranks better than 63.53% on this metric.
During the past 12 months, Tristel's average EBITDA Per Share Growth Rate was 24.50% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 6.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 10.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Tristel was 55.00% per year. The lowest was -20.20% per year. And the median was 17.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Tristel 3-Year EBITDA Growth Rate Related Terms
TSNLF vs ISRG, BDX, MDLN: 3-Year EBITDA Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Tristel's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Tristel's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.90% mean?
Tristel (TSNLF) has a 3-Year EBITDA Growth Rate of 17.90% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tristel and its competitors. This is near median its historical median of 17.80. According to the industry distribution chart, Tristel ranks #252 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 36.5%.
Is Tristel's 3-Year EBITDA Growth Rate too high?
Tristel's current 3-Year EBITDA Growth Rate of 17.90% is near median its 10-year median of 17.80. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.30. Tristel's value of 17.90% is 115.7% above this industry median. Based on the distribution chart, Tristel ranks #252 out of 691 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Tristel has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tristel's 3-Year EBITDA Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #252 out of 691 companies for 3-Year EBITDA Growth Rate. This puts Tristel in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.30. Tristel's value of 17.90% is 115.7% above this benchmark. While the company's 10-year median is 17.80 vs. the industry median of 8.30, Tristel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.30, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current 3-Year EBITDA Growth Rate of 17.90% is 115.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Tristel and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current 3-Year EBITDA Growth Rate is 17.90%, which is near median its own 10-year median of 17.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Fairly Valued. The stock's GF Value™ is $6.18, compared to a current price of $5.74 — trading 7.1% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.90%, which is near median its 10-year median of 17.80 and 115.7% above the Medical Devices & Instruments industry median of 8.30. Tristel's overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Tristel (TSNLF), the current 3-Year EBITDA Growth Rate is 17.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.74 is trading 7.1% below its estimated GF Value™ of $6.18.
GuruFocus considers Tristel to be Fairly Valued.
Key valuation signals for TSNLF:
3-Year EBITDA Growth Rate: 17.90% (near median its 10-year median of 17.80)
GF Value™: $6.18 vs. price of $5.74 (7.1% below fair value)
Industry Position: 115.7% above the Medical Devices & Instruments median (#252 of 691)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
95GF Score
Get the complete analysis for TSNLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
